Vaccines, Variants, and Measured Expectations—A Question and Answer Session with Judith A. Aberg, MD, a Leader in Infectious Diseases at Mount Sinai
Several worrisome new variants of SARS-CoV-2, the virus that causes COVID-19, have been detected within the United States since the COVID-19 vaccine rollout began in December, raising concerns about the nation’s ability to return to normal in 2021. Chief among these...
Why the New Johnson & Johnson Vaccine Will Help Lead to the End of the Pandemic
With the authorization of Johnson & Johnson’s new COVID-19 vaccine and its encouraging data, you might be wondering how it stacks up against the Pfizer-BioNTech and Moderna vaccines. Mount Sinai infectious diseases experts participated in the clinical trials for...
NYEE Employees Receive the COVID-19 Vaccine
George Wanna, MD, Chair of the Department of Otolaryngology at New York Eye and Ear Infirmary of Mount Sinai and Mount Sinai Beth Israel, was among the first employees to receive the vaccine. When asked why he decided to get the vaccine he said, “I took...
Why Testing New Medicines in a Diverse Population Is Important
Companies are working to develop new vaccines for COVID-19, and one of the many challenges is ensuring that clinical trials required to test the new medicines reflect the population at large in order to determine how effective the vaccines will be when...
Mount Sinai Employees Explain Why They Were Excited to Receive the New COVID-19 Vaccine
The first health care workers throughout the Mount Sinai Health System received the first new COVID-19 vaccine on Tuesday, December 15. For many, it was an exciting and emotional moment. For these front-line workers, and for the Health System, receiving...
mRNA Vaccine Technology Makes Its Extraordinary Debut
The mRNA technology used to create the first two COVID-19 vaccines from Pfizer Inc., and Moderna, Inc. will undoubtedly change the course of vaccine development for years to come.Both companies have “shown that the vaccines are extraordinary,” says Peter...
